Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4267
Source ID: NCT00306696
Associated Drug: Rosiglitazone
Title: Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus
Interventions: DRUG: Rosiglitazone|DRUG: spironolactone|DRUG: hydrochlorothiazide|DRUG: frusemide
Outcome Measures: Primary: Changes in Haematocrit following 7 days diuretic adminstration. | Secondary: Total body fluid & extracellular fluid, body weight, haematocrit & haemoglobin.
Sponsor/Collaborators: Sponsor: GlaxoSmithKline
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 388
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2002-10
Completion Date: 2004-01
Results First Posted:
Last Update Posted: 2016-09-15
Locations: GSK Investigational Site, Brussel, 1090, Belgium|GSK Investigational Site, Sint Gillis-Waas, 9170, Belgium|GSK Investigational Site, Winnipeg, Manitoba, R3E 3P4, Canada|GSK Investigational Site, Aarhus, DK-8000, Denmark|GSK Investigational Site, Hellerup, 2900, Denmark|GSK Investigational Site, Hvidovre, DK-2650, Denmark|GSK Investigational Site, Dommartin-Les Toul, 54201, France|GSK Investigational Site, Paris Cedex 18, 75877, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, 69115, Germany|GSK Investigational Site, Muenchen, Bayern, 80636, Germany|GSK Investigational Site, Muenchen, Bayern, 80805, Germany|GSK Investigational Site, Muenchen, Bayern, 81241, Germany|GSK Investigational Site, Neuss, Nordrhein-Westfalen, 41460, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, 55116, Germany|GSK Investigational Site, Blieskastel, Saarland, 66440, Germany|GSK Investigational Site, Dresden, Sachsen, 01307, Germany|GSK Investigational Site, Athens, 10676, Greece|GSK Investigational Site, N. Efkarpia, Thessaloniki, 564 29, Greece|GSK Investigational Site, Nikaia Piraeus, 184 54, Greece|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Bologna, Emilia-Romagna, 40138, Italy|GSK Investigational Site, Genova, Liguria, 16132, Italy|GSK Investigational Site, Milano, Lombardia, 21045, Italy|GSK Investigational Site, Acquavive delle Fonti (BA), Puglia, 70021, Italy|GSK Investigational Site, Perugia, Umbria, 06126, Italy|GSK Investigational Site, Utrecht, 3584 CJ, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Stavanger, N-4011, Norway|GSK Investigational Site, Tromsoe, Norway|GSK Investigational Site, Bialystok, 15-276, Poland|GSK Investigational Site, Krakow, 31-501, Poland|GSK Investigational Site, Lodz, 90-153, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Warszawa, 03-242, Poland|GSK Investigational Site, Bratislava, 813 69, Slovakia|GSK Investigational Site, Kosice, 041 90, Slovakia|GSK Investigational Site, Lubochna, 034 91, Slovakia|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Barcelona, 08022, Spain|GSK Investigational Site, Barcelona, 08097, Spain|GSK Investigational Site, Madrid, 28035, Spain|GSK Investigational Site, Madrid, 28040, Spain|GSK Investigational Site, Tarrasa, Barcelona, 08221, Spain|GSK Investigational Site, Newcastle Upon Tyne, Northumberland, United Kingdom|GSK Investigational Site, Rugby, Warwickshire, CV22 5PX, United Kingdom|GSK Investigational Site, London, United Kingdom
URL: https://clinicaltrials.gov/show/NCT00306696

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D116 Rosiglitazone small molecule DB00412 Details
D119 Spironolactone small molecule DB00421 Details
D296 Hydrochlorothiazide small molecule DB00999 Details
D199 Furosemide small molecule DB00695 Details